Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Earnings drop 47% in 4Q from $1.5 billion in charges

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis

4Q Revenues: $14.8 billion (+4%)

4Q Earnings: $1.2 billion (-47%)

FY Revenues: $58.6 billion (+16%)

FY Earnings: $9.2 billion (-7%)

Comments: Pharmaceuticals sales in quarter were up 4% to $8.3 billion. Alcon sales were $2.4 billion (+6%). Sandoz sales declined 5% to $2.3 billion due to additional competition for enoxaparin, the generic version of Lovenox. Vaccines and Diagnostics sales grew 86% to $671 million. Consumer Health was down 7% to $1.1 billion related to the temporary suspension of production at a U.S. Consumer Health site. Operating income grew 12% to $3.6 billion in the quarter and 14% to $15.9 billion for the year. Earnings in the quarter were impacted by $1.5 billion charges and a negative currency impact of 9%. Recently launched products — Gilenya, Tasigna, Lucentis, Galvus, Afinitor, Xolair and Onbrez Breezhaler — contributed to sales growth in the quarter and year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters